Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2020 / Nov / Case of the Month (9)
Histology Histology Training and education

Case of the Month

11/23/2020 Quick Read (pre 2022) 1 min read

Share

A 70-year-old woman presented with an erythematous papule, neither pruritic nor painful, on the right side of her chest. A biopsy of the lesion shows the following histopathology:

What is the most likely diagnosis?

a. Cutaneous B cell pseudolymphoma
b. Primary cutaneous marginal zone lymphoma
c. Primary cutaneous diffuse large B cell lymphoma, leg type
d. Primary cutaneous follicle center lymphoma 
e. CD4+ small- to medium-sized pleomorphic T cell lymphoma

Click here to register your guess.

We will reveal the answer next month.

Do you have an interesting case that you would like us to feature? Email it to edit@thepathologist.com.

Submitted by Muhammad Ahsan, Sahiwal Medical College, Sahiwal, Pakistan.

Answer to November's Case of the Month.

C. CD3

All others are typically positive in blastic plasmacytoid dendritic cell neoplasm (BPDCN), but can also be positive in other neoplasms, including acute myeloid leukemia.

BPDCN is a rare, clinically aggressive hematologic malignancy characterized by clonal expansion of precursors to plasmacytoid dendritic cells and with frequent cutaneous involvement (as seen in this case). The pattern of cutaneous involvement may include isolated areas with a purplish nodule or bruise-like papule. Alternatively, more disseminated purplish nodules/papules/macules may be present. Bone marrow involvement with associated cytopenias is also common and becomes increasingly likely with disease progression. Leukemic dissemination may also be present at diagnosis (1). Lymph nodes are involved in 40–50 percent of cases.

The male:female ratio is approximately 3:1. Patients are typically elderly, but can be any age (2). A subset of cases may develop in relation to other myeloid neoplasms, especially chronic myelomonocytic leukemia (3). Regardless of presentation, the prognosis of BPDCN remains poor, with median survival of one to two years.

Histologically, a diffuse, monotonous proliferation of medium-sized, blast-like cells with relatively scant, greyish-blue cytoplasm is appreciated. The nuclei have irregular contours with fine chromatin and one or several small nucleoli. There is typically extensive involvement of the dermis with extension into the subcutaneous fat but relative sparing of the epidermis. Lymph node involvement tends to be interfollicular with sparing of the B-cell nodules. Bone marrow involvement may range from interstitial to massive replacement. The bone marrow also frequently shows myelodysplastic features, particularly of the megakaryocytic lineage (4).

Several immunophenotypic markers are characteristic of BPDCN (5):

  • Positive: CD4, CD45RA, CD56, CD123, CD43, TCL1, CD303
  • Subset of cases: CD7, CD2 (rare), CD33, TdT, CD68 (small cytoplasmic dots), CD5, CD36, CD38, CD79a, CD117
  • Negative: CD3, CD13, CD16, CD19, CD20, lysozyme, myeloperoxidase, EBER

CD34 is typically negative by immunohistochemistry but may be positive by flow cytometry (6). Other recently described markers that may be useful include the transcription factor TCF4, which drives plasmacytoid dendritic cell development (7). In a subset of cases, negativity for CD4 or CD56 may occur and create further diagnostic challenge. S100 is positive in a subset of cases, including pediatric patients (2). In general, an extensive panel of stains may be required to confirm the diagnosis, due to potential overlap with other entities. Differential diagnoses to consider include:

  • Mature plasmacytoid dendritic cell proliferations, which may also be seen in chronic myelomonocytic leukemia and involve the skin. These show a mature morphology, low Ki67 proliferation rate, and are negative for CD56, but may express a range of other atypical antigens in the setting of a primary marrow disorder (1).
  • B- or T-cell lymphoblastic lymphoma. These typically express more B or T lineage markers in addition to TdT. CD10 is often positive and Ki67 proliferation rate is very high. In addition, clonal rearrangement of IG or TCR loci would be helpful.
  • Acute myeloid leukemia or myeloid sarcoma. These typically show MPO or lysozyme, CD13, and additional myeloid markers, but significant overlap with monocytic tumors expressing CD4, CD56, and CD123 may occur. BPDCN may also show CD68, but in a dot-like pattern.
  • In some cases of acute leukemia, definitive lineage cannot be assigned and may fall into one of the categories of acute leukemias of ambiguous lineage.

Molecular studies demonstrate germline TCR and immunoglobulin loci, although an associated T cell clone may be present in some cases. A subset of patients exhibits a complex karyotype, with recurrent abnormalities in chromosomes 5q, 12p, 13q, 6q, 15q, and 9 described (8). TET2 appears to be the most commonly mutated gene, with mutations in NRAS, ATM, MET, KRAS, IDH2, and KIT also reported (9).

The prognosis of the disease is poor. Patients may respond initially to therapy, but have subsequent relapse and disease resistance. The overall mean survival ranges from 10–22 months. Active areas of investigation include a better understanding of disease mechanisms and potential treatment strategies.

Courtesy of PathologyOutlines.com. Case by Gabriel Lerner (Boston University School of Medicine, Boston, Massachusetts, USA), Lija Joseph, Bethany Tierno, Rebecca Shore, and Murat Anamur (Lowell General Hospital, Lowell, Massachusetts, USA); discussion by Genevieve M. Crane, Cleveland Clinic, Cleveland, Ohio, USA.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. F Facchetti et al., Mod Pathol, 29, 98 (2016). PMID: 26743477.
  2. AG Jegalian et al., Haematologica, 95, 1873 (2010). PMID: 20663945.
  3. F Vitte et al., Am J Surg Pathol, 36, 1302 (2012). PMID: 22895265.
  4. K Alayed et al., Am J Hematol, 88, 1055 (2013). PMID: 23940084.
  5. T Petrella et al., Am J Clin Pathol, 123, 662 (2005). PMID: 15981806.
  6. L Martín-Martín et al., Oncotarget, 6, 19204 (2015). PMID: 26056082.
  7. M Ceribelli et al., Cancer Cell, 30, 764 (2016). PMID: 27846392.
  8. D Leroux et al., Blood, 99, 4154 (2002). PMID: 12010820.
  9. A Stenzinger et al., Oncotarget, 5, 6404 (2014). PMID: 25115387.

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Your Newest Colleague?
Histology
Your Newest Colleague?

January 6, 2022

1 min read

The need for AI-based end-to-end biomarkers in oncology

Biospecimen Access For Biotechs
Histology
Biospecimen Access For Biotechs

February 14, 2022

1 min read

Quality, provenance, and “taking pot luck”

Case of the Month
Histology
Case of the Month

February 21, 2022

1 min read

The Art of the Laboratory
Histology
The Art of the Laboratory

March 25, 2022

1 min read

For the seventh time, we asked you to share the images you think capture the most beautiful, educational, or amusing aspects of pathology – and you delivered. Welcome to our gallery tour of the most visually striking discipline in medicine!

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.